Barry Hendin

Key Takeaways Data shows that minority patients with multiple sclerosis (MS) experience a greater incidence of disability from the condition. However, few studies have explored the effects of MS and its treatments specifically on minority groups. A groundbreaking new study is evaluating the impact of a leading MS treatment on minority patients. Starting aggressive treatment early in the disease process can prevent permanent neurological damage and delay disability for people with MS.

Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a serious global health threat that has impacted healthcare delivery and accessibility across the globe. Individuals with chronic neuroimmunological diseases such as multiple sclerosis (MS) are of particular interest as they may be more vulnerable to infections due to treatment involving immunomodulatory disease modifying therapies (DMTs).

Publication HistoryPublished online: August 13, 2018Accepted: August 11, 2018; Received: June 6, 2018;